/
STOK
$32.39+$0.39 (+1.22%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.0B
62M shares
52-week range
$11.19 – $40.22
73% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.36%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.27
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $12.4M | $8.8M | $36.6M | $184.4M |
| Cost of revenue | $214.0K | $450.0K | $1.9M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$214.0K | −$450.0K | −$1.9M | $0 | $12.4M | $8.8M | $36.6M | $184.4M |
| Gross margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $8.4M | $23.3M | $32.2M | $54.2M | $77.8M | $82.2M | $89.1M | $137.9M |
| Operating income | −$12.8M | −$35.7M | −$53.0M | −$86.1M | −$104.4M | −$114.8M | −$101.4M | −$20.6M |
| EBITDA | −$12.6M | −$31.9M | −$50.3M | −$84.8M | −$99.5M | −$102.2M | −$86.8M | −$5.1M |
| Net income | −$12.5M | −$32.3M | −$52.2M | −$85.8M | −$101.1M | −$104.7M | −$89.0M | −$6.9M |
| Net margin | — | — | — | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| EPS (diluted) | -0.53 | -1.59 | -1.56 | -2.34 | -2.60 | -2.38 | -1.65 | -0.12 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $28M | $-3.23 | $-3.44–$-3.08 | 8 |
| 2027 | $46M | $-3.12 | $-3.71–$-2.20 | 7 |
| 2028 | $125M | $-1.95 | $-3.25–$-0.67 | 7 |
| 2029 | $341M | $0.32 | $0.08–$0.65 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Stoke Therapeutics, Inc. Common Stock
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
www.stoketherapeutics.com- Employees
- 170
- IPO / List date
- Jun 19, 2019
- HQ
- BEDFORD, MA
Held by traders on TradeandTell
No one on the platform currently holds STOK.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 178,300 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded STOK yet.
